Medicus Pharma Ltd. Warrant

NASDAQ:MDCXW USA
Market Cap
$6.68K
Market Cap Rank
#28086 Global
#9378 in USA
Share Price
$0.68
Change (1 day)
+0.00%
52-Week Range
$0.45 - $3.16
All Time High
$3.16
About

Medicus Pharma Ltd., a biotech/life sciences company, focuses on developing clinical development programs of therapeutic assets in the United States. It is developing SKNJCT-003, which is in Phase 2 study for the treatment of basal cell carcinoma of the skin. Medicus Pharma Ltd. has a strategic collaboration with the Gorlin Syndrome Alliance to access to SKINJECT in Patients with Gorlin Syndrome.… Read more

Medicus Pharma Ltd. Warrant (MDCXW) - Net Assets

Latest net assets as of September 2025: $-804.89K USD

Based on the latest financial reports, Medicus Pharma Ltd. Warrant (MDCXW) has net assets worth $-804.89K USD as of September 2025.

Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($9.98 Million) and total liabilities ($10.78 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.

Key Net Assets Metrics

Metric Value
Current Net Assets $-804.89K
% of Total Assets -8.07%
Annual Growth Rate N/A
5-Year Change N/A
10-Year Change N/A
Growth Volatility N/A

Medicus Pharma Ltd. Warrant - Net Assets Trend (2021–2024)

This chart illustrates how Medicus Pharma Ltd. Warrant's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.

Annual Net Assets for Medicus Pharma Ltd. Warrant (2021–2024)

The table below shows the annual net assets of Medicus Pharma Ltd. Warrant from 2021 to 2024.

Year Net Assets Change
2024-12-31 $3.13 Million +181.87%
2023-12-31 $1.11 Million +109.11%
2022-12-31 $-12.20 Million -16.11%
2021-12-31 $-10.51 Million --

Equity Component Analysis

This analysis shows how different components contribute to Medicus Pharma Ltd. Warrant's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

  • Retained earnings have decreased by 1818652200.0% over the analyzed period, potentially due to dividend distributions or operating losses.

Current Equity Component Breakdown (December 2024)

Component Amount Percentage
Common Stock $30.50 Million 973.56%
Other Components $1.52 Million 48.50%
Total Equity $3.13 Million 100.00%

Medicus Pharma Ltd. Warrant Competitors by Market Cap

The table below lists competitors of Medicus Pharma Ltd. Warrant ranked by their market capitalization.

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Medicus Pharma Ltd. Warrant's equity between the two most recent reporting periods.

Equity Growth Insights

  • From 2023 to 2024, total equity changed from 1,111,448 to 3,132,839, a change of 2,021,391 (181.9%).
  • Net loss of 11,155,516 reduced equity.
  • New share issuances of 7,519,716 increased equity.
  • Other factors increased equity by 5,657,191.

Equity Change Factors (2023 to 2024)

Factor Impact Contribution
Net Income $-11.16 Million -356.08%
Share Issuances $7.52 Million +240.03%
Other Changes $5.66 Million +180.58%
Total Change $- 181.87%

Book Value vs Market Value Analysis

This analysis compares Medicus Pharma Ltd. Warrant's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

  • Current price-to-book ratio: 2.56x
  • The company is trading above its book value, indicating the market recognizes value beyond its reported assets.

Historical Price-to-Book Ratios

Date Book Value per Share Market Price P/B Ratio
2021-12-31 $-5.57 $0.68 x
2022-12-31 $-2.45 $0.68 x
2023-12-31 $0.14 $0.68 x
2024-12-31 $0.27 $0.68 x

Capital Efficiency Dashboard

This dashboard shows how efficiently Medicus Pharma Ltd. Warrant utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

  • Current Return on Equity (ROE): -356.08%
  • The company may be facing challenges in efficiently utilizing shareholder equity.
  • DuPont Analysis Breakdown:
  • • Net Profit Margin: 0.00%
  • • Asset Turnover: 0.00x
  • • Equity Multiplier: 1.80x
  • Recent ROE (-356.08%) is below the historical average (-208.57%), suggesting potential challenges in capital efficiency.

Historical Capital Efficiency Metrics

Year Return on Equity Net Profit Margin Asset Turnover Equity Multiplier Economic Value Added
2021 0.00% 0.00% 0.00x 0.00x $-1.00 Million
2022 0.00% 0.00% 0.00x 0.00x $-472.58K
2023 -478.18% 0.00% 0.00x 1.70x $-5.43 Million
2024 -356.08% 0.00% 0.00x 1.80x $-11.47 Million

Industry Comparison

This section compares Medicus Pharma Ltd. Warrant's net assets metrics with peer companies in the same industry.

Industry Context

Peer Company Comparison

Company Net Assets Return on Equity Debt-to-Equity Market Cap
Medicus Pharma Ltd. Warrant (MDCXW) $-804.89K 0.00% N/A $11.07 Million
Abcam plc (ABCZF) $726.90 Million -1.17% 0.45x $5.00 Billion
Able View Global Inc. Warrant (ABLVW) $11.42 Million 85.41% 3.81x $277.93K
Above Food Ingredients Inc. Warrants (ABVEW) $199.86 Million -2.89% 0.00x $6.25 Million
Adamas Trust, Inc. (ADAMG) $2.43 Billion 7.94% 1.33x $2.09 Billion
ADS-TEC ENERGY PLC Warrant (ADSEW) $33.92 Million -162.39% 2.67x $10.06 Million
Alliance Entertainment Holding Corporation Warrants (AENTW) $52.92 Million 10.13% 4.23x $2.29 Million
Forafric Global PLC Warrants (AFRIW) $5.32 Million -457.58% 45.29x $2.67 Million
Centurion Acquisition Corp. Warrant (ALFUW) $282.84 Million 1.97% 0.05x $4.81 Million
Alliance Trust PLC (ALITF) $4.04 Billion 10.04% 0.29x $112.87K
Alvotech Warrant (ALVOW) $-564.42 Million 0.00% 0.00x $35.01 Million